Journal of Clinical Oncology
Articles in this Issue
Beyond cardio-renal outcomes with GLP-1RA and SGLT2i in anthracycline-treated diabetic women with breast cancer: A propensity score–matched analysis from Global Federated Health Research Network.
e23079 Background: Anthracyclines remain central to breast cancer therapy but are associated with cardiotoxicity and downs...
Final analysis of the efficacy and safety of oral S-1 for locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma: A multicenter retrospective study.
9586 Background: Anti–PD-1 antibodies are the standard systemic therapy for advanced cutaneous squamous cell carcinoma (cS...
Clinical outcomes in metastatic melanoma in Colombia: A retrospective cohort study from the REMMEC registry.
e21511 Background: Latin American melanoma data reflect distinct epidemiology and variable treatment access. REMMEC is a C...
Clinicopathological associations of p16 expression, high-risk HPV genotypes, and tumor-infiltrating lymphocytes on prognosis in anal squamous cell carcinoma.
e15503 Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy with an increasing incidence worldwide. Chroni...
Efficacy and safety of TACE combined with immune checkpoint inhibitors and VEGF inhibitors in hepatocellular carcinoma: A systematic review and meta-analysis.
e16300 Background: Transarterial chemoembolization (TACE) remains the standard of care for intermediate stage hepatocellul...
Screen failure and treatment dropout in oncology clinical trials: A multicenter analysis from Türki̇ye.
e23009 Background: Screen failure and treatment dropout remain major barriers to successful conduct of oncology clinical t...
HopeMove: Feasibility and acceptability of a mobile exercise app for pediatric patients undergoing cancer treatment.
10034 Background: Cancer related fatigue and reduced physical activity are common during pediatric cancer treatment and ne...
Stereotactic body radiotherapy plus cadonilimab and lenvatinib as conversion therapy for potentially resectable hepatocellular carcinoma (UniRTX): A phase II study.
e16278 Background: Successful conversion to resectability may improve survival in patients with potentially resectable hep...
Patterns of chemotherapy delivery following neuropathy in patients with stage I-IIIA breast cancer.
e12514 Background: Chemotherapy-induced neuropathy is a common toxicity during treatment for breast cancer and may prompt...
Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC).
4617 Background: In patients (pts) with MIBC, we tested the activity of neoadjuvant SG (SURE-01, NCT05226117), SG + pembro...
Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in patients with CPI-refractory cutaneous melanoma: Promising results from an ongoing phase 1/2 study.
9526 Background: Imneskibart (AU-007) is an AI designed monoclonal antibody binding to interleukin-2 (IL-2) preventing bin...
Cost-effectiveness of post-discharge home care for reducing potentially avoidable readmissions in stage IV cancer.
12031 Background: Approximately 39% of hospital readmissions among stage IV cancer patients are potentially avoidable. The...
Ultra–early-onset metastatic colorectal cancer (<35 years): RAS-driven, APC/TP53-depleted, TMB-low molecular features in a real-world analysis of 2,392 patients.
3542 Background: Early-onset colorectal cancer (CRC, <50 years) is on the rise globally and includes a biologically het...
Single cell analysis of recurrent/metastatic, platinum resistant nasopharyngeal cancer patients treated within the POINT trial: Transitional insights for future research.
e18028 Background: POINT trial treated platinum-resistant, recurrent/metastatic (RM) Nasopharyngeal Carcinoma (NPC) patien...
A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).
7003 Background: The epigenetic enzyme protein arginine methyltransferase 5 (PRMT5) plays a critical role in cell prolifer...
A pilot study exploring four meditation practices for anxiety among cancer survivors.
e24132 Background: Meditation has been associated with reductions in anxiety among cancer survivors. This study aims to ev...
Overall survival association of adjuvant endocrine therapy (ET) after pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in ER+/HER2+ early-stage breast cancer.
541 Background: In ER+/HER2+ early breast cancer, adjuvant ET is standard; however, its survival benefit for patients achi...
Impact of multidisciplinary rounds on time to treatment for veterans with lung cancer at a VA medical center.
e23281 Background: Delays in initiating lung cancer treatment adversely affect patient outcomes. In late 2024, increasing...
Enhancing cause-of-death attribution through real-world data integration: A framework to improve cancer mortality identification.
e23418 Background: Precise cause of death (COD) is essential for pharmaceutical and healthcare research in evaluating trea...
Association of survival with clinical characteristics and CD68/CD206 expression in stage IIIA squamous cell lung carcinoma.
e20027 Background: Stage IIIA squamous cell lung carcinoma (SqCLC) has a poor prognosis, with 5-year survival rarely excee...
Enabling blood-based mass spectrometry MRD detection in multiple myeloma without archived serum samples.
7556 Background: Minimal residual disease (MRD) assessment in multiple myeloma (MM) relies almost exclusively on bone marr...
Scaling digital patient navigation to improve access to multidisciplinary melanoma care.
1528 Background: Multidisciplinary (multiD) melanoma care is associated with improved patient (pt) outcomes, yet access is...
Safety and efficacy of nivolumab combined with brentuximab vedotin in patients with relapsed and refractory classic Hodgkin lymphoma: Systematic review and meta-analysis.
e19040 Background: Relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) remains a therapeutic challenge despite h...
Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression.
e23525 Background: Sarcomas are a heterogeneous group of mesenchymal malignancies frequently driven by pathognomonic chrom...
A phase II clinical study of PD-1 inhibitor tislelizumab combined with chemotherapy for unresectable recurrent locally advanced nasopharyngeal carcinoma (RETICULA-NPC trial).
e18061 Background: For unresectable locally rNPC patients, re-irradiation with intensity-modulated radiotherapy remains th...